Neisseria Meningitidis Infection - 19 Studies Found Estado Estudiar Completed Nombre del estudio: Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Condición: Meningococcal Disease Fecha: 2012-09-07 Intervenciones: Biological: MenACWY-CRM The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosacch Completed Nombre del estudio: Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers Condición: Meningococcal Disease Fecha: 2013-11-11 Intervenciones: Biological: MenACWY-CRM MenACW Completed Nombre del estudio: Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults Condición: Meningococcal Disease Fecha: 2007-11-16 Intervenciones: Biological: Men ACWY CRM A sin Completed Nombre del estudio: B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants Condición: Meningococcal Disease Fecha: 2007-06-19 Intervenciones: Biological: MenACWY-CRM One do Withdrawn Nombre del estudio: A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger Condición: Meningococcal Disease Fecha: 2011-02-08 Completed Nombre del estudio: One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age Condición: Meningococcal Disease Fecha: 2010-06-04 Intervenciones: Biological: rMenB+OMV NZ Subjects will be assigned to a study group based on the group assignment in the Completed Nombre del estudio: Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers Condición: Meningococcal Disease Fecha: 2009-02-18 Intervenciones: Biological: 1a - rMenB+OMV NZ and routine vaccines Completed Nombre del estudio: Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents Condición: Meningococcal Disease Fecha: 2014-05-06 Intervenciones: Biological: MenABCWY Effective Completed Nombre del estudio: Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules Condición: Meningococcal Disease Fecha: 2008-04-16 Intervenciones: Biological: rMenB+OMV NZ Other Completed Nombre del estudio: Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine Condición: Meningococcal Disease Fecha: 2009-12-04 Intervenciones: Biological: Meningococcal (group B) multicomponent recombinant adsorbed vacc Next >>>
